Phase 1Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
- Sponsor
- I-Mab Biopharma US Limited (Industry)
- Enrollment
- 330 planned
- Conditions
- Solid Tumor; Advanced Cancer; Metastatic Cancer; Gastric Cancer; Gastroesophageal Junction Carcinoma; Esophageal Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC)
- Interventions
- TJ033721 (givastomig); TJ033721 (givastomig) , nivolumab, chemotherapy; TJ033721 (givastomig), chemotherapy; TJ033721 (givastomig), durvalumab, chemotherapy
- Ages
- adults, older adults
- Registry
- NCT04900818
Full record on ClinicalTrials.gov
From the registry
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Primary outcomes
- Dose-limiting toxicities (DLTs)
- Incidence and severity of AEs
- Maximum tolerated or administered dose (MTD, MAD)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Model projects the most cytotoxic breast cancer chemotherapy costs 9.4 life-years through accelerated aging
The Georgetown-led simulation compared regimens in women ages 30–79 using blood p16 as an aging marker; JAMA Network Open published the findings.
Also in GEN (opens GEN in a new tab), Infobae (opens Infobae in a new tab), BES.media (opens BES.media in a new tab), xeu.mx (opens xeu.mx in a new tab)
